海普瑞(002399) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was ¥5,280,713,410.80, a decrease of 3.03% compared to ¥5,445,572,060.12 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥646,741,666.49, representing a significant increase of 182.57% from a loss of ¥783,258,039.42 in 2023[6]. - The cash flow from operating activities reached ¥2,194,132,237.51, marking a substantial increase of 450.99% compared to ¥398,215,676.99 in 2023[6]. - Basic earnings per share for 2024 were ¥0.4408, a turnaround from a loss of ¥0.5338 in 2023, reflecting an increase of 182.58%[6]. - The total assets at the end of 2024 were ¥17,343,523,964.97, a decrease of 9.69% from ¥19,203,415,131.24 at the end of 2023[6]. - The company reported a weighted average return on equity of 5.39% for 2024, an improvement of 11.99% from -6.60% in 2023[6]. - The company experienced a significant increase in net profit excluding non-recurring gains and losses, which was ¥253,544,139.42 in 2024 compared to a loss of ¥779,841,459.91 in 2023, an increase of 132.51%[6]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares to all shareholders, based on a total of 1,467,296,204 shares[5]. - The cash dividend plan for 2024 proposes a distribution of ¥366,824,051, with a per-share dividend of ¥2.50 based on a total share capital of 1,467,296,204 shares[157]. - The company will not distribute cash dividends or issue bonus shares for the 2023 fiscal year, as approved in the shareholder meeting[155]. Business Operations - The company has not reported any changes in its main business operations since its listing[20]. - The company operates under the supervision of the National Medical Products Administration and adheres to Good Manufacturing Practices (GMP)[15]. - The company's main business includes the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization[34]. - The heparin product line includes enoxaparin sodium preparations and heparin sodium raw materials, with a focus on high-quality and effective medications[35]. - The company has developed approximately 200 different molecular structures in the CDMO sector, demonstrating strong delivery records[38]. - The company provides comprehensive CDMO services, including development and cGMP manufacturing for biopharmaceuticals[43]. Market and Economic Environment - The company faced challenges in the global economy, with the IMF projecting global growth rates of 3.2% and 3.3% for 2024 and 2025 respectively[31]. - The company noted that the European economy is under pressure due to energy price fluctuations and geopolitical risks, impacting overall growth[31]. - The Asian market showed mixed performance, with China maintaining growth resilience despite internal demand weakening, while India is expected to exceed a growth rate of 6%[31]. - The company has seen a 5% year-on-year growth in GDP, indicating a positive economic environment for its operations[33]. Research and Development - R&D expenses increased by 16.23% to CNY 212,035,640.41, primarily due to increased investment in research projects[77]. - The company aims to enhance product quality through advanced research projects, including the synthesis of heparin precursors and polysaccharides[79]. - The company plans to accelerate the drug development process for RVX-208, which has received breakthrough therapy designation from the FDA[65]. - The company is committed to optimizing organizational structure and resource allocation to improve operational efficiency and profitability[111]. Risk Management - The company has detailed its future risks and corresponding mitigation strategies in the report[5]. - The company faces risks associated with new drug development, including potential failures during clinical trials, and will continue to manage resources effectively to advance its pipeline[117]. - The company faces significant foreign exchange risk due to major revenues coming from overseas markets, primarily settled in euros and US dollars, which may lead to substantial exchange gains or losses[118]. - The company has established a financial derivatives trading management system to mitigate risks associated with derivative transactions[100]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[125]. - The company maintains a transparent information disclosure system, ensuring all investors have equal access to information[127]. - The company has implemented a strict insider information management system, with no reported insider trading incidents during the reporting period[128]. - The company actively engages with investors to enhance understanding and communication, adhering to investor relations management regulations[127]. Environmental Compliance - The company strictly adhered to multiple environmental protection laws and standards during its operations, including the Air Pollution Prevention and Control Law[169]. - The company holds valid pollution discharge permits for its facilities, with the latest permit for the Pingshan plant valid until October 29, 2029[170]. - The company reported a total emission of VOCs at 2.979 tons per year, which is within the regulatory limits[171]. - The company has established comprehensive wastewater and waste gas treatment facilities, ensuring that wastewater discharge is below the total amount approved by the discharge permit[175]. Employee and Management Structure - The total number of employees at the end of the reporting period is 1,926, with 839 in the parent company and 1,087 in major subsidiaries[150]. - The professional composition includes 680 production personnel, 123 sales personnel, 787 technical personnel, 64 financial personnel, and 272 administrative personnel[150]. - The company emphasizes a competitive and fair compensation policy, aligning employee remuneration with performance and market standards[152]. - The company has a performance evaluation system for determining the remuneration of directors and senior management[141].